For all the advances that have been made in it, drug discovery is still a hit or miss process, as much an art as a science. But new technologies are changing that, allowing companies to approach the process with more precise eye. On today’s episode of the pharmaphorum podcast, Jason Park, CEO of Empress Therapeutics, discusses his company's novel approach to small molecule drug discovery.